Revised IPSET-Thrombosis for Essential Thrombocythaemia: Clinical Guide

Clinical guide to Revised IPSET-Thrombosis for Essential Thrombocythaemia with input guidance, calculation method, interpretation, worked example, limitations, FAQs and references.

Classifies thrombosis risk in essential thrombocythaemia using age, thrombosis history and JAK2 V617F mutation status. This clinical guide explains the inputs, method, interpretation, limitations and evidence supporting the tool.

Overview

Revised IPSET-Thrombosis for Essential Thrombocythaemia is a Haematology tool that uses the required clinical variables to produce a structured clinical result. Use it only for the purpose and patient population described by the calculator.

Clinical Significance

The result supports consistent assessment, calculation and communication. It should be combined with the full history, examination, investigations, trajectory of illness and current local guidance.

When to Use

  • Use when the clinical question matches the stated purpose of Revised IPSET-Thrombosis for Essential Thrombocythaemia.
  • Confirm that the patient falls within the population for which the method is intended.
  • Use current and accurately measured inputs, with the correct units and definitions.

How It Is Calculated

  • The calculator applies the established Revised IPSET-Thrombosis for Essential Thrombocythaemia formula, criteria or scoring logic to the entered variables.

Interpretation

  • Very low: age ≤60, no thrombosis history and JAK2 wild type. Low: age ≤60, no thrombosis history and JAK2 mutated. Intermediate: age >60, no thrombosis history and JAK2 wild type. High: previous thrombosis or age >60 with JAK2 mutation.

Worked Example

Enter a clinically consistent example set of the required variables. The calculator applies the established Revised IPSET-Thrombosis for Essential Thrombocythaemia logic and displays the resulting value or category with its interpretation.

Patient Considerations

  • Consider age, comorbidity, pregnancy, organ dysfunction, treatment already given and whether the patient differs from the original validation population.
  • Review trends and clinical deterioration rather than relying only on a single calculation.

Limitations

  • The tool may perform differently outside its derivation and validation settings.
  • Missing, estimated, delayed or incorrectly converted inputs can materially alter the result.
  • The calculation cannot account for every diagnosis, contraindication or urgent clinical feature.

Clinical Pearls

  • Check every input against the calculator definition before submission.
  • Document the component values as well as the final score or calculated result.
  • Repeat the calculation when relevant observations, laboratory results or treatment change.

Common Mistakes

  • Using the tool for an ineligible patient or a different clinical purpose.
  • Entering values in the wrong units or selecting a category from incomplete information.
  • Allowing a reassuring result to override significant symptoms, examination findings or clinical deterioration.

Evidence Base

Revised IPSET-Thrombosis for Essential Thrombocythaemia is based on the established equation, criteria or scoring system implemented in the calculator. Clinical performance depends on the original evidence, subsequent validation and correct application to the intended population.

Frequently Asked Questions

What is Revised IPSET-Thrombosis for Essential Thrombocythaemia used for?

Classifies thrombosis risk in essential thrombocythaemia using age, thrombosis history and JAK2 V617F mutation status.

Which inputs are required?

The calculator uses the clinical variables displayed on the form. Check all units and category definitions before entry.

Can the result be used on its own?

No. It supports but does not replace clinical assessment, investigation, local pathways or specialist advice.

When should the calculation be repeated?

Repeat it when a relevant clinical observation, laboratory value, treatment or the patient’s condition changes.

References

  1. Barbui T et al. Blood Cancer J. 2015;5:e369. doi:10.1038/bcj.2015.94. — Primary publication or authoritative guidance supporting this calculator.
  2. Barbui T et al. Blood. 2012;120:5128–5133. — Primary publication or authoritative guidance supporting this calculator.

Reviewed by: MedicalC Clinical Editorial Team
Last reviewed: July 2026

Return to calculator